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Abstract 
Objectives: Recent guidance recommended use of high-sensitivity troponin for rapid rule out of 
myocardial infarction (MI) in the English health service. We aimed to determine the extent of 
implementation of this guidance across English hospitals. 
Methods: Cross-sectional questionnaire survey of 131 English acute hospitals with over 10,000 
admissions per year. 
Results: We received 125/131 responses (95%), with 110/125 (88%) reporting use of a high-
sensitivity troponin assay and responses showing progressive implementation over the last ten 
years. High-sensitivity troponin was reported to be used for rapid rule out of MI in 92/110 Trusts 
(84%). Review of guidelines received from 95/110 Trusts identified that 71/95 (75%) provided 
guidance for rapid MI rule out with high-sensitivity troponin: 57 recommended testing at zero 
and three hours, four recommended testing at zero and two hours, nine recommended testing 
at zero and one hour, and timing was unclear at one Trust. 
Conclusions: English acute hospital Trusts report widespread implementation of high-sensitivity 
troponin for rapid MI rule out with most recommending testing at zero and three hours. 
What is already known 
x High-sensitivity troponin can be used to rule out MI within a few hours of arrival at 
hospital 
x Recent guidance recommends using high-sensitivity troponin to rule out MI in the 
English health service 
 
What this paper adds 
x English acute hospital Trusts report widespread implementation of high-sensitivity 
troponin for rapid MI rule out 
x Most hospitals providing guidelines recommended testing at zero and three hours 
Background 
Emergency admissions (requiring provision of a hospital bed) to English hospitals with 
unspecified chest pain  increased from 118,828 in 1998-9 to a peak of 248,197 in 2010-11 before 
falling to 232,598 in 2017-18 (1). The most likely reason for admission for these cases is to rule 
out myocardial infarction (MI). The recent development of high-sensitivity troponin assays offer 
the potential to allow rapid rule out of MI and thus reduce admissions with chest pain. In 2014 
new guidance from the National Institute for Health and Care Excellence (NICE) recommended 
using high-sensitivity troponin assays to rule out MI within three hours of hospital attendance 
(2), which was incorporated into updated NICE chest pain guidance in 2016 (3). We aimed to 
determine whether NICE guidance regarding the use of high-sensitivity troponin to rule out MI 
has been implemented across English hospitals. 
 
Methods 
We conducted a survey of all acute NHS hospital Trusts in England with more than 10,000 
emergency admissions in the year 2017/2018 ?ĞǆĐůƵĚŝŶŐĐŚŝůĚƌĞŶ ?ƐĂŶĚŵĂƚĞƌŶŝƚǇŚŽƐƉŝƚĂůƐ (1). 
We sent a short questionnaire through email and online forms via a freedom of information 
(FOI) access request to 131 eligible Trusts in April 2019. The questionnaire was designed to be 
completed with minimal time and effort, using readily available information, and is shown in 
appendix 1. The questionnaire was sent to the FOI administrator but it was not possible to 
determine who subsequently provided the information. Trust guidelines or protocols were 
reviewed to determine the timing of troponin sampling and whether troponin measurements 
were used to rule out MI within four hours of hospital admission. This was determined by the 
last sample being no later than three hours from hospital arrival or initial sampling to allow for 
time taken to take blood and retrieve results.  
 
Results 
We received 125/131 (95%) responses between April and August 2019, with 110 (88%) reporting 
use of a high-sensitivity troponin assay. Figure 1 shows the number of Trusts introducing the 
assay per year (excluding three that did not respond to this question), indicating progressive 
implementation over the last ten years. Around half implemented high-sensitivity assays before 
the 2014 NICE guidance and half after. 
The assay used was manufactured by Roche in 63/110 (57%) Trusts, Abbott in 16 (14%), 
Beckman Coulter in 12 (11%) and Siemens in 12 (11%), with one Trust using both Roche and 
Abbott assays and six (5%) not responding to this question. It is worth noting that the NICE 
guidance only recommended the Elecsys Troponin T high-sensitive assay (Roche) and the 
ARCHITECT STAT High Sensitive Troponin- I (Abbott) for clinical use, while the AccuTnI +3 assay 
(Beckman Coulter) was only recommended for clinical research. The threshold for positivity was 
reported by 97/110 Trusts, with 79 using the 99th percentile (54 sex-specific, 25 overall), 12 
using a higher threshold and six using a lower threshold, of which three appeared to be the Limit 
of Detection. 
High-sensitivity troponin was reported to be used for rapid rule out of MI in 92/110 Trusts 
(84%), with one additional Trust reporting use for rule out in only one of its two sites. We 
received copies of guidelines from 95/110 Trusts. Review of the guidelines identified 71/95 
(75%) using high-sensitivity troponin for rapid MI rule out: 57 recommended testing at zero and 
three hours, four recommended zero and two hours, nine recommended zero and one hour, 
and timing was unclear at one Trust. 
 
Discussion 
English acute hospital Trusts report widespread use of high-sensitivity troponin for rapid rule 
out of MI, suggesting that recent NICE guidance has been widely implemented. Most hospitals 
use high-sensitivity troponin and most of these use it for rapid MI rule out. The most commonly 
used assay is the Roche high-sensitivity troponin T. Timing of sampling varies, with most Trusts 
recommending sampling at zero and three hours, but some recommending shorter time 
intervals. The findings suggest that availability of high-sensitivity troponin has increased since a 
survey of 94 hospital laboratories in 2015 reported that 60% had implemented a high-sensitivity 
troponin assay (4). A recent international survey reported that 72% of 80 UK sites use high-
sensitivity troponin, with serial sampling at 3-6 hours in 78% (5). Our findings report a slightly 
higher use of high-sensitivity troponin (88%) across a larger and potentially more representative 
sample, with additional detail regarding timings and assays used. 
The survey has strengths and limitations. The response rate was high, facilitated by the FOI 
request and simple design, thus ensuring a comprehensive sample of English Trusts. A 
disadvantage of this approach is that we were unable to specify or determine who completed 
the survey. It is limited to England, so it is unclear whether similar uptake of high-sensitivity 
troponin testing has occurred in the devolved nations of the United Kingdom. It describes 
reported practice rather than actual practice, so it is unclear whether the guidance presented is 
actually followed. 
The last point is probably the most salient. Our survey suggests progressive implementation of 
NICE guidance across the English NHS that may be reflected in admission rates for chest pain, 
which have plateaued and started to fall after showing a progressive rise prior to 
implementation of high-sensitivity troponin (1). However, NICE guidance anticipated that 
implementation would lead to markedly reduced admissions, which is not yet obvious from 
routinely available data. It has been suggested elsewhere (6) that high-sensitivity troponins 
could lead to over-diagnosis and over-investigation. Further research could explore whether 
implementation of high-sensitivity troponin testing at different times across different Trusts 
over the last decade is associated with an effect on admissions with chest pain. 
As noted in the results, NICE did not recommend the Beckman-Coulter assay as a high sensitivity 
assay and Seimens have only recently released a high sensitivity assay. The 22% of Trusts 
reporting use of these assays may therefore not have genuinely been using a high sensitivity 
assay. 
In conclusion, English acute hospital Trusts report widespread implementation of high-sensitivity 
troponin for rapid MI rule out with most recommending testing at zero and three hours. 
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